Table 1. Participant details and interviews conducted at both timepoints.
| CCG or PCN | Participants per CCG or PCN | Participant ID (CCG or PCN)a | Interviews | Self-reported roleb | Years in rolec | |
|---|---|---|---|---|---|---|
| Timepoint 1 | Timepoint 2 | |||||
| A | 1 | A1 (CCG) | Dec 2020 | Feb 2021 | Head of medicines optimisation | 1–3 |
| B | 3 | B1 (PCN) | Dec 2020 | Feb 2021 | Senior PCN pharmacist | 1–3 |
| B2 (PCN) | Dec 2020 | Feb 2021 | Senior PCN pharmacist | <1 | ||
| B3 (CCG) | Dec 2020 | Feb 2021 | Senior pharmacist | >3 | ||
| C | 2 | C1 (CCG) | Dec 2020 | Feb 2021 | Prescribing adviser | >3 |
| C2 (CCG) | Dec 2020 | Feb 2021 | Practice pharmacist | <1 | ||
| D | 2 | D1 (PCN) | Dec 2020 | May 2021 | Senior PCN pharmacist | <1 |
| D2 (CCG) | Dec 2020 | Apr 2021 | Pharmaceutical adviser | 1–3 | ||
| E | 2 | E1 (PCN) | Dec 2020 | Feb 2021 | PCN pharmacist | <1 |
| E2 (CCG) | Jan 2021 | Apr 2021 | Senior medicines optimisation pharmacist | 1–3 | ||
| F | 2 | F1 (CCG) | Dec 2020 | – | Medicines optimisation technician | >3 |
| F2 (CCG) | Dec 2020 | Feb 2021 | Medicines optimisation pharmacist | >3 | ||
| G | 2 | G1 (PCN) | Dec 2020 | Feb 2021 | Prescribing champion (senior GP partner) | >3 |
| G2 (CCG) | Jan 2021 | Mar 2021 | Head of medicines optimisation | >3 | ||
| Total | 14 (9 CCG & 5 PCN) | 14 | 13 | |||
| 27 | ||||||
aParticipants from one organisation were from a commissioning support unit (CSU). CSUs provide a range of support activities to CCGs: for the purpose of this study, and for anonymity, they are treated as, and reported as, CCGs. bModified slightly to preserve anonymity. cRole durations classified for representativeness and anonymity: three were >3 years (5.5, 6.5, and 20 years); one PCN was formed only 3 months before the interview, the study team decided to include this PCN despite the participant thus being in the role <6 months; this was categorised as <1 year.
CCG = clinical commissioning group. PCN = primary care network.